Advancing Alzheimer's Treatment: CEO Discusses Promising Phase 2 Data and Multi-dimensional Drug Approach | Remi Barbier, CEO, Cassava Sciences Inc. 00:10:00

Share On Facebook Share On Twitter

A CEO of a biotech company specializing in Alzheimer's treatment discusses promising phase 2 trial data for their investigational drug targeting neuroinflammation and neurodegeneration, shedding light on its potential impact and complexities in addressing the disease.

Recent Videos